

## SIDLEY AUSTIN BROWN &amp; WOOD LLP

CHICAGO  
DALLAS  
NEW YORK  
SAN FRANCISCO  
SEATTLE  
WASHINGTON, D.C.

555 WEST FIFTH STREET  
LOS ANGELES, CALIFORNIA 90013  
TELEPHONE 213 896 6000  
FACSIMILE 213 896 6600  
www.sidley.com  
FOUNDED 1866

BEIJING  
HONG KONG  
LONDON  
SHANGHAI  
SINGAPORE  
TOKYO

FACSIMILE/TELECOPIER TRANSMISSION

**From:** Name: Nisan A. Steinberg, Ph.D.; 213 896 6644  
 Voice Phone: Ann Weiss 213 896 6170

**To:** Name: Examiner M. Schmidt  
 Company:  
 Facsimile #: 703 746 5264  
 Voice Phone:  
 Subject: 09/545,428 and 09/488,491

Message:

Dear Examiner Schmidt:

Pursuant to our conversation of today, transmitted herewith are the documents concerning two applications as follows:

1. Re application of Levesque

Serial No.: 09/545,428, Filed April 7, 2000  
 Our Docket No. CEDAR-44526 (18810-80380)

a. Terminal Disclaimer re 6,087,168 (filed today, by facsimile transmission)

and

2. Re application of: Levesque

Serial No.: 09/488,491, Filed January 20, 2002  
 Our Docket No.: CEDAR-42638 (18810-80382)

a. Response to Office Action (filed in the USPTO on February 14, 2002)

Date: 02/25/02 Time: 12:52 PM No. Pages (Including Cover): 29

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE US POSTAL SERVICE. THANK YOU.

Note: If you do not receive all the pages, please call: Ann Weiss 213 896 6170

CEDAR-44526 (18810-80380

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Levesque  
Serial No. 09/545,428  
Filed: April 7, 2002  
For: Transdifferentiation of Transfected Epidermal Basal Cells  
Cells  
Examiner: M. Schmidt  
Unit: 1635

**CERTIFICATE OF MAILING BY FACSIMILE**

Assistant Commissioner for Patents  
Washington, D. C. 20231

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING FACSIMILE TRANSMITTED TO EXAMINER M. SCHMIDT  
AT 703/746-5264 IN THE UNITED STATES PATENT AND  
TRADEMARK OFFICE, WASHINGTON, DC 20231, ON

February 25, 2002.

DATE February 25, 2002

BY   
Ann Weiss

**Terminal Disclaimer To Obviate A Double  
Patenting Rejection Over A Prior Patent**

Docket No.

CEDAR-044526 (18810-80380)

In Re Application Of: Levesque et al.

Serial No.	Filing Date	Examiner	Group Art Unit
09/545,428	April 7, 2000	Schmidt, M.	1635

## Invention:

**TRANSDIFFERENTIATION OF TRANSFECTED EPIDERMAL BASAL CELLS INTO NEURAL  
PROGENITOR CELLS, NEURONAL CELLS AND/OR GLIAL CELLS**

Owner of Record: CEDARS-SINAI MEDICAL CENTER

**TO THE ASSISTANT COMMISSIONER FOR PATENTS:**

The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,087,168. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1.  For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2.  The undersigned is an attorney of record.



Signature

Dated: February 25, 2002

Nisan A. Steinberg, Ph.D., Reg. No. 40,345

Typed or Printed Name

Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.  
 PTO suggested wording for terminal disclaimer was unchanged.  
 Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.